Topic
Resection
54 Podcasts • 36 Cases • 9 Courses on BackTable
Episode # 323 • 11 Aug 2026
Managing Intermediate-Risk Bladder Cancer
Recurrent low-grade, intermediate-risk bladder cancer presents a unique treatment challenge: recurrence is common, progression is uncommon, and the burden of repeated procedures can add up quickly. On this episode of the BackTable Urology Podcast, Dr. Ruchika Talwar interviews Dr. Charles "Chas" Peyton about how to manage intermediate-risk bladder cancer patients while balancing disease control and quality of life. They discuss the cumulative impact of repeated TURBTs and explore the evolving role of office-based treatments and chemoablative therapies as alternatives to the traditional treatment cycle.
More on Resection
Loading recent podcasts…
Urology # 323
Aug 10, 2026
with Dr. Charles Peyton, Dr. Ruchika Talwar
Recurrent low-grade, intermediate-risk bladder cancer presents a unique treatment challenge: recurrence is common,...
690+ listens
Tumor Board # 67
Jun 17, 2026
with Dr. Sunil Patel, Dr. Kristen Scarpato, Dr. Bogdana Schmidt
Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate...
40+ listens
Tumor Board # 63
Jun 3, 2026
with Dr. Amy Luckenbaugh, Meredith Donahue NP, Dr. Bogdana Schmidt
Are traditional bladder cancer care models falling behind as new therapies flood the field and reshape the landscape?...
280+ listens
Vascular & IR # 644
May 11, 2026
with Dr. Neil Mehta, Dr. Ari Cohen, Dr. Venkatesh Krishnasamy
A high-functioning HCC tumor board can turn complex transplant decisions into coordinated treatment plans that account...
1,200+ listens
Vascular & IR # 660
Jul 2, 2026
with Dr. David Madoff, Dr. Michael Barraza
How is portal vein embolization (PVE) pushing the boundaries of liver tumor resectability, and what does it take to...
1,600+ listens
Vascular & IR # 653
Jun 8, 2026
with Dr. Beau Toskich, Dr. Christopher Malone, Dr. Venkatesh Krishnasamy
How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases?...
1,500+ listens
Vascular & IR # 649
May 26, 2026
with Dr. Nima Kokabi, Dr. Riad Salem, Dr. Zach Berman
Can the right dosimetry approach turn palliative Y90 into a curative therapy? In this episode of the BackTable 2026 HCC...
1,400+ listens
Vascular & IR # 642
May 6, 2026
with Dr. Beau Toskich, Dr. Zach Berman, Dr. Venkatesh Krishnasamy
Complete pathologic necrosis (CPN) rates above 90%? This week’s BackTable episode from the 2026 HCC Creator Weekend™ is...
80+ listens
ENT Case
Apr 20, 2026
with Dr. Joao Paulo Almeida, Dr. Zara Patel, Dr. Garret Choby and Dr. Satyan Sreenath
ENT Case
Apr 20, 2026
with Dr. Joao Paulo Almeida, Dr. Zara Patel, Dr. Garret Choby and Dr. Satyan Sreenath
VI Case
Jul 7, 2025
with Dr. Tyler Sandow, Dr. Zach Berman and Dr. Venkatesh Krishnasamy
VI Case
Jul 7, 2025
with Dr. Tyler Sandow, Dr. Zach Berman and Dr. Venkatesh Krishnasamy
ENT Case
Apr 20, 2026
with Dr. Joao Paulo Almeida, Dr. Zara Patel, Dr. Garret Choby and Dr. Satyan Sreenath
ENT Case
Apr 20, 2026
with Dr. Joao Paulo Almeida, Dr. Zara Patel, Dr. Garret Choby and Dr. Satyan Sreenath
VI Case
Jul 7, 2025
with Dr. Tyler Sandow, Dr. Zach Berman and Dr. Venkatesh Krishnasamy
VI Case
Apr 1, 2026
with Dr. Alex Villalobos, Dr. Nima Kokabi, Dr. Brian Funaki and Dr. Venkatesh Krishnasamy
VI Course
2.5 hours, 28 lessons
Tumor Board Course
2 CME/CE credits, 2.5 hours, 19 lessons
Tumor Board Course
2 CME/CE credits, 2.5 hours, 26 lessons
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.